AbbVie
ABBV
#26
Rank
NZ$691.65 B
Marketcap
NZ$391.34
Share price
-1.15%
Change (1 day)
34.26%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : NZ$236.27 Billion

According to AbbVie's latest financial reports the company's total liabilities are NZ$236.27 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

AbbVie - Total liabilities on balance sheet (from 2011 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31NZ$233.69 B18.88%
2023-12-31NZ$196.57 B2.71%
2022-12-31NZ$191.39 B-0.28%
2021-12-31NZ$191.92 B0.74%
2020-12-31NZ$190.52 B31.89%
2019-12-31NZ$144.45 B42.92%
2018-12-31NZ$101.07 B9.28%
2017-12-31NZ$92.49 B4.24%
2016-12-31NZ$88.73 B23.67%
2015-12-31NZ$71.74 B118.13%
2014-12-31NZ$32.89 B9.4%
2013-12-31NZ$30.06 B4.6%
2012-12-31NZ$28.74 B195.59%
2011-12-31NZ$9.72 B38.11%
2010-12-31NZ$7.04 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Pfizer
PFE
NZ$200.16 B-15.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$135.51 B-42.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$157.66 B-33.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$139.38 B-41.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$64.18 B-72.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$19.04 B-91.94%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$106.08 B-55.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$118.54 B-49.83%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$2.18 B-99.08%๐Ÿ‡บ๐Ÿ‡ธ USA